Literature DB >> 3488775

von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma.

L Holmberg, E Berntorp, M Donnér, I M Nilsson.   

Abstract

In eight members of one family, platelets in platelet-rich plasma aggregated at much lower ristocetin concentrations than normal. Ivy bleeding time was variously prolonged, and von Willebrand factor antigen (vWF:Ag), ristocetin cofactor activity, and factor VIII coagulant activity were decreased. Most of the affected members had had slight to rather severe bleeding symptoms. Platelet-type von Willebrand's disease (vWD) could be ruled out. All multimers of vWF:Ag were found in plasma as well as platelets. Administration of 1-desamino-8-D-arginine vasopressin (DDAVP) to the propositus did not cause thrombocytopenia, and platelet-poor plasma obtained immediately after did not aggregate normal platelets. The molecular defect in this family, inherited as an autosomal dominant, resembles the one in type IIB because of the response to ristocetin but differs from IIB because all vWF:Ag multimers are present in plasma and the response to DDAVP is atypical. We conclude that this family has a new subtype of vWD and propose that structural as well as functional criteria should be used for a proper classification of vWD.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488775

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  At least type VWD2B is a discrete variant of VWD, isn't it?

Authors:  Robert R Montgomery
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113

Review 2.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 3.  Von Willebrand's disease.

Authors:  I M Nilsson; S Lethagen
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

4.  Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.

Authors:  Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

5.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2.

Authors:  Omid Seidizadeh; Luciano Baronciani; Maria Teresa Pagliari; Giovanna Cozzi; Paola Colpani; Andrea Cairo; Simona Maria Siboni; Eugenia Biguzzi; Flora Peyvandi
Journal:  Blood Adv       Date:  2022-07-12

7.  Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins.

Authors:  Yuta Kato; Atsushi Iwata; Makito Futami; Motoki Yamashita; Satoshi Imaizumi; Takashi Kuwano; Amane Ike; Makoto Sugihara; Hiroaki Nishikawa; Bo Zhang; Shin'ichiro Yasunaga; Keijiro Saku; Shin-Ichiro Miura
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

8.  A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

Authors:  Frédéric Adam; Caterina Casari; Nicolas Prévost; Alexandre Kauskot; Cécile Loubière; Paulette Legendre; Christelle Repérant; Dominique Baruch; Jean-Philippe Rosa; Marijke Bryckaert; Philip G de Groot; Olivier D Christophe; Peter J Lenting; Cécile V Denis
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.